Compare FNWD & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | ORMP |
|---|---|---|
| Founded | 1994 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.1M | 197.6M |
| IPO Year | 1996 | 2010 |
| Metric | FNWD | ORMP |
|---|---|---|
| Price | $43.66 | $4.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.7K | ★ 134.8K |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | 1.10% | ★ 6.07% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | 1.00 | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $10.81 | N/A |
| Revenue Next Year | $5.26 | N/A |
| P/E Ratio | $43.41 | ★ $1.49 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $30.05 | $2.09 |
| 52 Week High | $45.90 | $5.47 |
| Indicator | FNWD | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 38.29 |
| Support Level | $42.56 | $3.91 |
| Resistance Level | $44.01 | $4.22 |
| Average True Range (ATR) | 0.83 | 0.16 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 95.15 | 38.69 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.